Thursday, November 21, 2024 11/21/2024

Immune Landscape of Anal Cancer and Survival Outcomes in People with HIV (Immuno/Microenvironment)

Award Number: P30CA068485
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

PROJECT SUMMARY/ABSTRACT HIV is associated with a 30-fold increased lifetime risk of anal cancer. Altered immunity, not simply immunodeficiency, is one proposed mechanism driving this excess risk, and the significantly worse outcomes observed following a cancer diagnosis compared to individuals without HIV. The immune milieu is likely a major factor contributing to these cancer disparities among people living with HIV (PWH). However, few studies have examined the anal tumor immune landscape by HIV status and the associated with cancer outcomes. Chemoradiation therapy is the standard treatment for anal cancer; however, ~30% of anal cancer cases recur and this is similar for people with and without HIV. Further, treating anal cancer recurrence comes with detrimental side effects and morbidity. The persistence of chemoradiation therapy as the standard of care is due the rarity of anal cancer and the difficulty of completing large, randomized clinical trials. Identification of biomarkers that can predict at-risk individuals with unfavorable treatment outcomes is urgently needed. It is likely that additional molecular events besides HPV are required for anal cancer development and these molecular events are likely associated with disease recurrence. Overall, not much is known about the transcriptomic and immunologic signatures of anal cancer treatment differences. Thus, evaluating the full transcriptomic and immunologic profile of anal cancer tissue would be a logical first step to help elucidate when, where, and to what extent biological aberrations facilitate treatment outcomes for anal cancer. To address the gap in the field, we have established a clinical cohort at Vanderbilt University Medical Center that links to all electronic health record data and tissue biorepository to maximize sample utility with enriched clinical data for this rare cancer. We will conduct the following specific aims using pre-treatment tissues from anal cancer patients with and without HIV: (1) examining differences in the transcriptomic profiling of anal cancer tissue by HIV status identify clinical biomarkers for cancer outcomes using RNA-seq; (2) evaluate differences in tumor immune profiles by HIV status and cancer outcomes using spatial transcriptomics; (3) assess transcriptomic and immunologic biomarkers in longitudinal samples from patients who had recurrent anal cancer. Building upon our preliminary studies in PWH, the proposed innovative study is the first to investigate the immune and transcriptomic landscape of anal cancer recurrence. Results from this study have high translational implications as it will a) will identify at-risk individuals who may require alternate treatment or close monitoring and care management and b) understand the biology of anal cancer and pathogenesis. The biomarkers identified could help to improve cancer treatment targets to inform development of future, more efficacious treatment strategies tailored to anal cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	000	29	11/13/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $7,615,067 )
2024	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	001	29	8/28/2024	NON-COMPETING CONTINUATION	$7,263,544
2024	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	002	29	9/3/2024	SUPPLEMENT FOR EXPANSION	$250,000
2024	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	003	29	9/4/2024	SUPPLEMENT FOR EXPANSION	$250,000
2024	2024	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	004	29	9/19/2024	SUPPLEMENT FOR EXPANSION	$0
2024	2020	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	000	24	10/1/2023	SUPPLEMENT FOR EXPANSION	-$148,477
														Subtotal = $7,615,067

Issue Date FY: 2023 ( Subtotal = $7,520,726 )
2023	2023	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	001	28	8/8/2023	SUPPLEMENT FOR EXPANSION	$257,182
2023	2023	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	000	28	8/7/2023	NON-COMPETING CONTINUATION	$7,263,544
2023	2023	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	002	28	8/14/2023	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $7,520,726

Issue Date FY: 2022 ( Subtotal = $7,573,898 )
2022	2022	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	005	27	8/12/2022	SUPPLEMENT FOR EXPANSION	$59,999
2022	2022	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	004	27	8/11/2022	NON-COMPETING CONTINUATION	$7,271,076
2022	2022	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	006	27	8/31/2022	SUPPLEMENT FOR EXPANSION	$242,823
2022	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	007	26	9/21/2022	SUPPLEMENT FOR EXPANSION	$0
2022	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	002	26	6/14/2022	SUPPLEMENT FOR EXPANSION	$0
2022	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	001	26	6/8/2022	NON-COMPETING CONTINUATION	$0
2022	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	000	26	10/20/2021	NON-COMPETING CONTINUATION	$0
2022	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	003	26	6/14/2022	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $7,573,898

Issue Date FY: 2021 ( Subtotal = $8,131,073 )
2021	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	007	26	9/14/2021	NON-COMPETING CONTINUATION	$7,271,074
2021	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	006	25	7/12/2021	SUPPLEMENT FOR EXPANSION	$600,000
2021	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	008	26	9/15/2021	SUPPLEMENT FOR EXPANSION	$59,999
2021	2021	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	009	26	9/20/2021	SUPPLEMENT FOR EXPANSION	$200,000
2021	2020	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	004	25	3/25/2021	COMPETING CONTINUATION	$1,740,475
2021	2020	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	005	24	3/25/2021	SUPPLEMENT FOR EXPANSION	-$595,000
2021	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	001	24	3/25/2021	SUPPLEMENT FOR EXPANSION	-$118,377
2021	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	000	24	3/25/2021	NON-COMPETING CONTINUATION	-$627,869
2021	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	003	24	3/25/2021	SUPPLEMENT FOR EXPANSION	-$200,000
2021	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	002	24	3/25/2021	SUPPLEMENT FOR EXPANSION	-$199,229
														Subtotal = $8,131,073

Issue Date FY: 2020 ( Subtotal = $8,031,319 )
2020	2020	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	000	24	6/8/2020	SUPPLEMENT FOR EXPANSION	$595,000
2020	2020	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	002	25	9/21/2020	SUPPLEMENT FOR EXPANSION	$150,000
2020	2020	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	001	25	9/15/2020	COMPETING CONTINUATION	$7,286,319
														Subtotal = $8,031,319

Issue Date FY: 2019 ( Subtotal = $6,370,700 )
2019	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	000	24	8/16/2019	NON-COMPETING CONTINUATION	$5,853,094
2019	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	003	24	9/12/2019	SUPPLEMENT FOR EXPANSION	$199,229
2019	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	004	24	9/13/2019	SUPPLEMENT FOR EXPANSION	$200,000
2019	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	001	24	8/27/2019	SUPPLEMENT FOR EXPANSION	$118,377
2019	2019	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	002	24	8/30/2019	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $6,370,700

Issue Date FY: 2018 ( Subtotal = $6,741,085 )
2018	2018	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	002	23	9/13/2018	SUPPLEMENT FOR EXPANSION	$249,999
2018	2018	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	001	23	9/12/2018	SUPPLEMENT FOR EXPANSION	$118,377
2018	2018	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	003	23	9/14/2018	SUPPLEMENT FOR EXPANSION	$199,229
2018	2018	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	005	23	9/18/2018	SUPPLEMENT FOR EXPANSION	$120,443
2018	2018	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	004	23	9/17/2018	SUPPLEMENT FOR EXPANSION	$199,943
2018	2018	VANDERBILT UNIVERSITY MEDICAL CENTER	1161 21ST AVE S STE D3300 MCN	NASHVILLE	TN	37232	DAVIDSON	USA	Cancer Centers Support Grants	000	23	9/11/2018	NON-COMPETING CONTINUATION	$5,853,094
														Subtotal = $6,741,085

Issue Date FY: 2017 ( Subtotal = $6,434,248 ) (Continued on the next page)
Grand Total All Awards = $154,917,008

Page 1 of 3 (138 items)12 3

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Immune Landscape of Anal Cancer and Survival Outcomes in People with HIV (Immuno/Microenvironment)

Award Number: P30CA068485

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer